



## YOUR EXPERIENCE

in the use of PrBOTOX® (onabotulinumtoxinA) for the following indications:

### Focal spasticity

- The management of focal spasticity, including the treatment of upper limb spasticity associated with stroke in adults
- The symptomatic treatment of lower limb spasticity associated with stroke in adults
- Symptomatic treatment of upper and/or lower limb spasticity in pediatric patients two years of age or older. BOTOX is not intended as a replacement for usual standard of care regimens and is not likely to be effective in improving range of motion at a joint affected by a fixed contracture

### Blepharospasm

- The treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age or older

### Cervical dystonia

- To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults

## OUR COMMITMENT

to raising awareness and providing education for patients and healthcare professionals throughout the treatment journey, including:

-  Ongoing support with our AbbVie Care Support Program
-  Public and private coverage across Canada (criteria applies)
-  Disease awareness through patient organizations
-  Healthcare professional education
-  Local, regional and national events
-  Presence at national congresses



### For more information:

Please consult the Product Monograph at: [https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/BOTOX\\_PM\\_EN.pdf](https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/BOTOX_PM_EN.pdf) for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-668-6424.

**REFERENCE:** Current BOTOX Product Monograph, AbbVie Corporation.

BOTOX and its design are trademarks of AbbVie Corporation.  
© 2022 AbbVie. All rights reserved.

